Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean‐Yves Blay(Université Claude Bernard Lyon 1), Margaret von Mehren(Temple University Health System), Patrick Schöffski(KU Leuven), Hans Gelderblom(Leiden University Medical Center), Rodrigo Ruiz‐Soto(Deciphera Pharmaceuticals (United States)), Sebastian Bauer(Science for Life Laboratory), Gina Z. D’Amato(University of Miami Health System), Peter Reichardt(Helios Hospital Berlin-Buch), Robin L. Jones(Institute of Cancer Research), César Serrano(Vall d'Hebron Institut de Recerca), Steven Attia(Mayo Clinic in Florida), Suzanne George(Dana-Farber Cancer Institute), Michael C. Heinrich(VA Portland Health Care System), Julie Meade(Deciphera Pharmaceuticals (United States)), John Zalcberg(Monash Health), Kelvin Shi(Deciphera Pharmaceuticals (United States)), Ping Chi(Memorial Sloan Kettering Cancer Center)
Cited by 406
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k